LSN News › Singapore

World · Singapore Bureau

Singapore biotech firm develops peptide treatment for pet infections

Healbac is collaborating with local veterinary clinics to test a novel peptide-based therapy designed to combat bacterial infections in companion animals while reducing reliance on chemical preservatives.

LSN Singapore · 14 November 2026

Singapore biotech firm develops peptide treatment for pet infections

A Singapore-based start-up is advancing a peptide-based treatment aimed at addressing infections in cats and dogs, marking a potential shift in veterinary medicine toward alternatives to conventional chemical preservatives.

Healbac has initiated a trial programme in partnership with six veterinary clinics across Singapore to evaluate the efficacy of its peptide formulation against common bacterial infections in companion animals. The biotech company's approach leverages peptide technology, which mimics naturally occurring antimicrobial compounds, to provide an alternative pathway for infection management.

The move aligns with broader industry trends toward developing more targeted and sustainable therapeutic options for animal health. By focusing on peptide-based solutions, Healbac seeks to address concerns associated with traditional chemical preservatives, which have long been standard in veterinary pharmaceuticals and pet care products.

The collaborative trial with local veterinary clinics will provide data on the treatment's safety and effectiveness in real-world clinical settings. Results from the programme are expected to inform next steps for the company's product development and potential commercialisation strategy.

The initiative reflects Singapore's growing position as a hub for biotech innovation in the Asia-Pacific region, where start-ups are increasingly applying advanced biological science to address gaps in animal health and wellness.